Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
Mark M. Awad(Memorial Sloan Kettering Cancer Center), Raphael Bueno(Brigham and Women's Hospital), Peter S. Hammerman(Broad Institute), Jessie M. English(Dana-Farber Cancer Institute), Christina Almonte(Dana-Farber Cancer Institute), Kwok‐Kin Wong(NYU Langone Health), Kai W. Wucherpfennig(Dana-Farber Cancer Institute), Shohei Koyama(Osaka City University), William G. Richards(Brigham and Women's Hospital), Julianne Barlow(Brigham and Women's Hospital), Pasi A. Jänne(Harvard University), Scott J. Rodig(Brigham and Women's Hospital), David A. Barbie(Dana-Farber Cancer Institute), Elena V. Ivanova(Massachusetts General Hospital), Patrick H. Lizotte(Harvard University), Lauren Keogh(Dana-Farber Cancer Institute), Xiaoyun Liao(Bristol-Myers Squibb (Germany)), Adam J. Bass(Dana-Farber Cancer Institute), F. Stephen Hodi(Harvard University), Lynette M. Sholl(Brigham and Women's Hospital), Hongye Liu(Dana-Farber Cancer Institute), Robert E. Jones(Beth Israel Deaconess Medical Center), Mark Bittinger(Dana-Farber Cancer Institute), Abigail Santos(Dana-Farber Cancer Institute), Meghana Kulkarni(Dana-Farber Cancer Institute), Grit S. Herter-Sprie(University of Cologne)
Cited by 71
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
Comprehensive molecular profiling of lung adenocarcinoma
|Nature|2014|5.9k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k